Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 18/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | GLS2 | Q9UI32 | 3/20 | 1.00 |
| ▸ | MPEG1 | Q2M385 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28164201 | 1.00 | ALOX5 (1.00) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL18586437 | 1.00 | ALOX5 (1.00) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL31040564 | 1.00 | ALOX5 (1.00) | ALOX5PTGS2GLS2MPEG1 | |
| Primin SCHEMBL362895 | 0.98 | ALOX5 (1.00) | ALOX5PTGS2GLS2MPEG1 | |
| Irisquinone A SCHEMBL13246144 | 0.91 | ALOX5 (0.83) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL9578753 | 0.88 | ALOX5 (0.78) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL9578749 | 0.88 | ALOX5 (0.78) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL11779155 | 0.84 | ALOX5 (0.71) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL11023972 | 0.84 | ALOX5 (0.71) | ALOX5PTGS2GLS2MPEG1 | |
| SCHEMBL30595957 | 0.84 | ALOX5 (0.71) | ALOX5PTGS2GLS2MPEG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10993920-B2 | 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic | Middle Tennessee State University (US) | 2021-05-04 | — | — | US | claimed |
| EP-3230249-B1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | MIDDLE TENNESSEE STATE UNIV (US) | 2020-04-08 | — | — | EP | claimed |
| US-20170360722-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2017-12-21 | — | — | US | claimed |
| EP-3230249-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2017-10-18 | — | — | EP | claimed |
| WO-2016094554-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2016-06-16 | — | — | WO | claimed |
| CN-118634204-A | Nanometer preparation of carambola root extract and application thereof in preparing medicament for treating diabetic nephropathy | 广西医科大学第一附属医院 | 2024-09-13 | — | — | CN | disclosed |
| CN-118634204-A | Nanometer preparation of carambola root extract and application thereof in preparing medicament for treating diabetic nephropathy | 广西医科大学第一附属医院 | 2024-09-13 | — | — | CN | disclosed |
| CN-117618316-B | Fermentation composition, mask and preparation method and application thereof | 广州市科臣生物技术有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-117618316-A | Fermentation composition, mask and preparation method and application thereof | 广州市科臣生物技术有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-114940645-A | Method for extracting carambola root benzoquinone chemical component crude extract | 星荣口腔护理用品(扬州)有限公司 | 2022-08-26 | — | — | CN | disclosed |
| US-10993920-B2 | 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic | Middle Tennessee State University (US) | 2021-05-04 | — | — | US | disclosed |
| US-10993920-B2 | 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic | Middle Tennessee State University (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3230249-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2017019888-A1 | CIS-AND TRANS-SUFFRUTICOSOL D AS THERAPEUTIC AGENTS | Middle Tennessee State University (US) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016094554-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094554-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094554-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | Middle Tennessee State University (US) | 2016-06-16 | — | — | WO | disclosed |
| CN-104861008-A | Method for extraction and separation of prunasin from Averrhoa carambola L. root | UNIV GUANGXI MEDICAL | 2015-08-26 | — | — | CN | disclosed |
| CN-103965270-A | Extraction and separation method for prunasin from root of Averrhoa carambola L. | UNIV GUANGXI MEDICAL | 2014-08-06 | — | — | CN | disclosed |
| CN-102140060-A | Method for extracting and separating crude extracts of carambola root quinones chemical components | RENBIN HUANG | 2011-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10993920-B2 | 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione as a cancer therapeutic | DCUN1D1, DCUN1D5, DDB1 | ALOX5 1437/4885PTGS2 3611/4885GLS2 3482/4885 |
| US-20170360722-A1 | 2-DODECYL-6-METHOXYCYCLOHEXA-2,5-DIENE-1,4-DIONE AS A CANCER THERAPEUTIC | DCUN1D1, DCUN1D5, DDB1 | ALOX5 1437/4885PTGS2 3611/4885GLS2 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.